#PLRZ

4 days ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study Polyrizon (Nasdaq: PLRZ) announced successful GMP manufacturing of a clinical trial material (CTM) batch with Eurofins CDMO AmatsiAquitaine S.A.S on March 10, 2026. The GMP batch follows two development batches showing batch-to-batch consistency and stability and supports a planned U.S. clinical study later in 2026.This milestone advances Polyrizon's intranasal platform toward clinical testing and regulatory submissions for its lead product candidate.

#PLRZ Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

www.stocktitan.net/news/PLRZ/polyrizon-anno...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product Polyrizon (Nasdaq: PLRZ) announced a comparative pre-clinical study showing its naloxone nasal formulation achieved 94.6% (±4.0%) deposition in the nasal vestibule and upper turbinate versus 79.6% (±3.0%) for a commercial reference product.The study used a validated silicone nasal cast and quantitative imaging; Polyrizon reported lower lower-turbinate deposition (5.4% vs. 20.4%), which may reduce posterior runoff and improve dosing consistency for intranasal systemic delivery.

#PLRZ Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

www.stocktitan.net/news/PLRZ/polyrizon-anno...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon”

#PLRZ Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

www.stocktitan.net/news/PLRZ/polyrizon-adva...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet Polyrizon (Nasdaq: PLRZ) said on January 13, 2026 that its board authorized exploring strategic investments in revenue-generating operating companies in defense, aviation, and artificial intelligence (AI). The company emphasized it remains fully committed to advancing its core intranasal medical pipeline, including PL-14, PL-16 and the Trap & Target intranasal delivery platform.The board said it will leverage a reported strong cash position and a debt-free balance sheet to pursue selective investments intended to generate near-term revenue while maintaining focus on clinical and regulatory progress.

#PLRZ Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

www.stocktitan.net/news/PLRZ/polyrizon-to-e...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

NASARIX: a new nasal spray brand designed to shield against allergens Polyrizon completes branding for PL-14 allergy blocker as NASARIX, built on its Capture and Contain hydrogel and screened for U.S. and EU markets.

#PLRZ Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

www.stocktitan.net/news/PLRZ/polyrizon-comp...

0 0 0 0

Market Wire News

@marketwirenews.com

2 months ago

News; ( NASDAQ: #PLRZ ) US Companies Moving the Markets, Morning edition <br>Mon, Jan 05, 2026 as of 10.00 am ET

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating

#PLRZ Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

www.stocktitan.net/news/PLRZ/polyrizon-anno...

0 0 0 0

Market Wire News

@marketwirenews.com

2 months ago

Just In: ( NASDAQ: #PLRZ ) US Companies Moving the Markets, Evening edition <br>Fri, Jan 02, 2026 as of 4:00 pm ET

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated Polyrizon (Nasdaq: PLRZ) highlighted its PL-16 Viral Blocker nasal spray as a complementary, non-pharmaceutical layer of protection during the intensifying 2025–2026 U.S. flu season. Public-health context includes CDC estimates of at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths, and a reported ~3 million fewer vaccine doses administered compared with last year.Polyrizon describes PL-16 as a hydrogel that forms a temporary physical barrier on nasal mucosa; preclinical in‑vitro studies reportedly showed over 90% protection of cells from varied viruses. On Dec 19, 2025 the company submitted a Pre-Request for Designation to the FDA as an OTC product to reduce viral exposure.

#PLRZ As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

www.stocktitan.net/news/PLRZ/as-flu-surge-c...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet Polyrizon (Nasdaq: PLRZ) said on Dec 29, 2025 that its board has authorized exploration of realistic investments in revenue-generating real assets while maintaining focus on its core intranasal medical pipeline.The company reiterated commitment to product development, preclinical and clinical studies, and regulatory progress for programs including PL-14 (allergy blocker), PL-16 (viral blocker), and the Trap & Target intranasal drug-delivery platform. The board cited the company’s strong cash position and debt-free balance sheet as enabling factors and said updates will be provided if material developments occur.

#PLRZ Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

www.stocktitan.net/news/PLRZ/polyrizon-to-e...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses Polyrizon (PLRZ) said on Dec 19, 2025 it submitted a Pre-Request for Designation (Pre-RFD) to the U.S. FDA for PL-16 Viral Blocker, a non‑pharmacological intranasal product designed to form a temporary physical barrier on the nasal mucosa to reduce exposure to influenza and cold viruses.The company reported that PL-16 showed over 90% protection in cell-based tests and that the Pre-RFD opens a formal regulatory dialogue about the appropriate pathway based on formulation and physical mode of action.The release cites CDC model estimates for the 2025–2026 flu season (at least 2.9M symptomatic illnesses, 1.4M medical visits, 30,000 hospitalizations, and 1,200 deaths) as context for respiratory‑infection risk.

#PLRZ Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

www.stocktitan.net/news/PLRZ/polyrizon-subm...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program Polyrizon (Nasdaq: PLRZ) reported preclinical results for its intranasal naloxone hydrogel on December 11, 2025, showing three supporting data pillars: stability, superior mucoadhesion versus a marketed product (p < 0.0001), and rapid permeation comparable to the commercial benchmark.The company completed permeation studies in a validated artificial membrane system and found no statistically significant difference in naloxone diffusion rates versus the reference product, indicating enhanced nasal residence time did not delay drug permeation. Polyrizon says these results support potential advancement of the candidate and highlight its Trap & Target™ hydrogel as a way to combine mucosal retention with fast onset.

#PLRZ Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

www.stocktitan.net/news/PLRZ/polyrizon-anno...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announces that it has successfully completed a pre-submission meeting with the U.S. Food and Drug

#PLRZ Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

www.stocktitan.net/news/PLRZ/polyrizon-comp...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Most Searched, Thursday December 4, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Dec 4th - #PLRZ #BTBT #IRBT #PMI #DNN #SERV #RR #QCLS #PLUG #BBAI #SMX #SG #SBET #SANA #QUBT #ONDS #LAC #INKT #CMCL #USAR - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product Polyrizon (Nasdaq: PLRZ) reported preclinical ex-vivo results on Dec 3, 2025 showing its proprietary naloxone Trap and Target (T&T) hydrogel adhered to rabbit nasal mucosa longer than a marketed intranasal naloxone spray.In a 30-minute simulated nasal wash study using residual fluorescence quantification, the hydrogel retained significantly higher fluorescence than the commercial product (p < 0.0001, two-way ANOVA), indicating stronger mucoadhesion that may support prolonged nasal residence and potentially improved intranasal absorption.

#PLRZ Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

www.stocktitan.net/news/PLRZ/polyrizon-repo...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Most Searched, Tuesday December 2, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Dec 2nd - #IBRX #RR #WEN #IQ #BTE #TAOP #EB #EXK #BTBT #DNN #BBAI #ABTC #PLRZ #VSCO #TLRY #SMX #ONDS #FSLY #BITF #$AEO - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Leading Indicators, Tuesday December 2, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Tue Dec 2nd - #TAOP #PLRZ #MYSZ #LOT #GLBS #DXST #THH #LTRX #LESL #FIEE #FBYD #SBXD #EB #CIO - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Stock Master

@stockmaster70.bsky.social

3 months ago

📢 Stocks Trending NOW: #BYND #MDB #CRDO #PLRZ #MRVL #JSPR #ALAB #SNOW #FTEL #TAOP

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform Polyrizon (Nasdaq: PLRZ) announced the successful completion of a key manufacturing upscaling milestone for its intranasal C&C platform on Dec 2, 2025. The company and its CDMO transitioned PL-14 from small-batch lab production to a larger-scale controlled run that validated key formulation parameters and showed the PL-14 formulation can be reliably produced at increased batch volumes while maintaining quality.The batch is intended to support clinical trial material (CTM) for a clinical trial expected to commence in 2026 and is described as produced in line with U.S. and European regulatory standards, advancing readiness for clinical and regulatory activities and potential future commercial manufacturing.

#PLRZ Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

www.stocktitan.net/news/PLRZ/polyrizon-anno...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation Polyrizon (Nasdaq: PLRZ) reported positive in‑vitro results for its intranasal gel candidate PL‑16 Viral Blocker on Nov 6, 2025. Tests in cell models showed broad-spectrum blocking against respiratory viruses including H1N1, with high cell viability and no cytotoxicity.Mechanistic experiments indicated the effect is reversible and physical: virus particles recovered infectivity after the formulation was removed, showing the product forms a temporary mucosal barrier rather than pharmacologically inactivating virus. Company plans clinical studies and regulatory review.

#PLRZ Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

www.stocktitan.net/news/PLRZ/polyrizon-demo...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy Polyrizon (Nasdaq: PLRZ) announced positive pre-clinical results for its intranasal formulation PL-14 on October 6, 2025. The study measured penetration of the house dust mite allergen Der p 1 through a PL-14 hydrogel barrier.Key measured results: 1.07% penetration at 1 hour, 1.14% at 2 hours and 13.6% at 4 hours. The study used allergen loads described as tens of times higher than typical real-world exposures. Polyrizon said PL-14 formed an effective nasal barrier and plans to initiate clinical studies to support regulatory and clinical pathways.

#PLRZ Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

www.stocktitan.net/news/PLRZ/polyrizon-anno...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Revolutionary Allergen-Blocking Nasal Spray: Polyrizon's PL-14 Takes Major Step Toward FDA Review Biotech firm Polyrizon submits comprehensive FDA pre-submission package for PL-14, a novel nasal spray barrier targeting allergic rhinitis. Product aims to block multiple allergens including pollen and dust mites.

#PLRZ Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

www.stocktitan.net/news/PLRZ/polyrizon-subm...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

60% Nasal Protection: Polyrizon's New Allergy Blocker Shows Promise in $210M Growing Market Biotech firm Polyrizon's PL-14 achieves 60% nasal vestibule deposition in preclinical study. Part of C&C platform targeting $0.21B allergen blocker market by 2033, growing at 4.4% CAGR.

#PLRZ Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

www.stocktitan.net/news/PLRZ/polyrizon-repo...

0 0 0 0

Banking With Billy

@stocktradex.bsky.social

7 months ago

StockTradeX JOIN STOCK TRADE X Membership 🛑 https://discord.gg/TvxGNK7gvq 🛑 Stock Trade X is your go-to source for **stock market analysis, trading strategies, and momentum plays**. Stay ahead with **catalyst-d...

🚀 $DFLI +335%, $PLRZ +170%, $BLNE +330% — micro float monsters detonating off real catalysts! Battery tech, biotech, and fintech all ripping. Watch: www.youtube.com/@StockTradeX 💬 Discord: discord.gg/TvxGNK7gvq #BillyBanks #DFLI #PLRZ #BLNE #BreakoutStocks #Momentum #LowFloat #StockTradeX

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

7 months ago

Nasdaq: #PLRZ
#Polyrizon_Bio reports strong preclinical data for PL-14, its intranasal allergy blocker. With over 60% nasal vestibule targeting, the hydrogel shows promise as a frontline defense against allergic rhinitis. Shares have risen 45% on the news.
prismmarketview.com/polyrizon-re...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study Polyrizon (Nasdaq: PLRZ) has announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating successful intranasal delivery in a collaborative study with the University of Parma. The study showed over 60% deposition of the product in the nasal vestibule, the critical first point of contact for airborne allergens.The research validates the company's proprietary Capture & Contain (C&C) platform, supporting its mechanism of action as a physical barrier against allergens. The global allergen blocker market, valued at $0.14 billion in 2024, is projected to reach $0.21 billion by 2033, growing at a 4.4% CAGR. The company plans to advance toward clinical trials following these encouraging preclinical results.

#PLRZ Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

www.stocktitan.net/news/PLRZ/polyrizon-repo...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel Polyrizon (Nasdaq: PLRZ) has successfully retained its Nasdaq listing following a hearing with the Nasdaq Hearings Panel. The company faced potential delisting concerns related to a private placement involving 5,962,073 ordinary shares, including 5,829,389 shares issued through warrant exercises. The Panel granted continued listing subject to meeting the Minimum Bid Price Rule by October 17, 2025.Following the private placement, Polyrizon reports a cash balance of $15.68 million. The company has committed to avoiding complex financing instruments and is implementing enhanced internal controls for securities issuances and Nasdaq compliance.

#PLRZ Polyrizon Retains Nasdaq Listing Following Hearings Panel

www.stocktitan.net/news/PLRZ/polyrizon-reta...